Cargando…

Umbilical cord-derived Wharton’s jelly for regenerative medicine applications

BACKGROUND: The last decade has seen an explosion in the interest in using biologics for regenerative medicine applications, including umbilical cord-derived Wharton’s Jelly. There is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid, and extracellular vesicl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ashim, El-Amin, Saadiq F., Levy, Howard J., Sze-Tu, Rebecca, Ibim, Sobrasua E., Maffulli, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017504/
https://www.ncbi.nlm.nih.gov/pubmed/32054483
http://dx.doi.org/10.1186/s13018-020-1553-7
_version_ 1783497207770513408
author Gupta, Ashim
El-Amin, Saadiq F.
Levy, Howard J.
Sze-Tu, Rebecca
Ibim, Sobrasua E.
Maffulli, Nicola
author_facet Gupta, Ashim
El-Amin, Saadiq F.
Levy, Howard J.
Sze-Tu, Rebecca
Ibim, Sobrasua E.
Maffulli, Nicola
author_sort Gupta, Ashim
collection PubMed
description BACKGROUND: The last decade has seen an explosion in the interest in using biologics for regenerative medicine applications, including umbilical cord-derived Wharton’s Jelly. There is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes in these products. The present study reports the development of a novel Wharton’s jelly formulation and evaluates the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes. METHODS: Human umbilical cords were obtained from consenting caesarian section donors. The Wharton’s jelly was then isolated from the procured umbilical cord and formulated into an injectable form. Randomly selected samples from different batches were analyzed for sterility testing and to quantify the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles. RESULTS: All samples passed the sterility test. Growth factors including IGFBP 1, 2, 3, 4, and 6, TGF-α, and PDGF-AA were detected. Several immunomodulatory cytokines, such as RANTES, IL-6R, and IL-16, were also detected. Pro-inflammatory cytokines MCSFR, MIP-1a; anti-inflammatory cytokines TNF-RI, TNF-RII, and IL-1RA; and homeostatic cytokines TIMP-1 and TIMP-2 were observed. Cytokines associated with wound healing, ICAM-1, G-CSF, GDF-15, and regenerative properties, GH, were also expressed. High concentrations of hyaluronic acid were observed. Particles in the extracellular vesicle size range were also detected and were enclosed by the membrane, indicative of true extracellular vesicles. CONCLUSION: There are numerous growth factors, cytokines, hyaluronic acid, and extracellular vesicles present in the Wharton’s jelly formulation analyzed. The amount of these factors in Wharton’s jelly is higher compared with other biologics and may play a role in reducing inflammation and pain and augment healing of musculoskeletal injuries.
format Online
Article
Text
id pubmed-7017504
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70175042020-02-20 Umbilical cord-derived Wharton’s jelly for regenerative medicine applications Gupta, Ashim El-Amin, Saadiq F. Levy, Howard J. Sze-Tu, Rebecca Ibim, Sobrasua E. Maffulli, Nicola J Orthop Surg Res Research Article BACKGROUND: The last decade has seen an explosion in the interest in using biologics for regenerative medicine applications, including umbilical cord-derived Wharton’s Jelly. There is insufficient literature assessing the amount of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes in these products. The present study reports the development of a novel Wharton’s jelly formulation and evaluates the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles including exosomes. METHODS: Human umbilical cords were obtained from consenting caesarian section donors. The Wharton’s jelly was then isolated from the procured umbilical cord and formulated into an injectable form. Randomly selected samples from different batches were analyzed for sterility testing and to quantify the presence of growth factors, cytokines, hyaluronic acid, and extracellular vesicles. RESULTS: All samples passed the sterility test. Growth factors including IGFBP 1, 2, 3, 4, and 6, TGF-α, and PDGF-AA were detected. Several immunomodulatory cytokines, such as RANTES, IL-6R, and IL-16, were also detected. Pro-inflammatory cytokines MCSFR, MIP-1a; anti-inflammatory cytokines TNF-RI, TNF-RII, and IL-1RA; and homeostatic cytokines TIMP-1 and TIMP-2 were observed. Cytokines associated with wound healing, ICAM-1, G-CSF, GDF-15, and regenerative properties, GH, were also expressed. High concentrations of hyaluronic acid were observed. Particles in the extracellular vesicle size range were also detected and were enclosed by the membrane, indicative of true extracellular vesicles. CONCLUSION: There are numerous growth factors, cytokines, hyaluronic acid, and extracellular vesicles present in the Wharton’s jelly formulation analyzed. The amount of these factors in Wharton’s jelly is higher compared with other biologics and may play a role in reducing inflammation and pain and augment healing of musculoskeletal injuries. BioMed Central 2020-02-13 /pmc/articles/PMC7017504/ /pubmed/32054483 http://dx.doi.org/10.1186/s13018-020-1553-7 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gupta, Ashim
El-Amin, Saadiq F.
Levy, Howard J.
Sze-Tu, Rebecca
Ibim, Sobrasua E.
Maffulli, Nicola
Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title_full Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title_fullStr Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title_full_unstemmed Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title_short Umbilical cord-derived Wharton’s jelly for regenerative medicine applications
title_sort umbilical cord-derived wharton’s jelly for regenerative medicine applications
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017504/
https://www.ncbi.nlm.nih.gov/pubmed/32054483
http://dx.doi.org/10.1186/s13018-020-1553-7
work_keys_str_mv AT guptaashim umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications
AT elaminsaadiqf umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications
AT levyhowardj umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications
AT szeturebecca umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications
AT ibimsobrasuae umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications
AT maffullinicola umbilicalcordderivedwhartonsjellyforregenerativemedicineapplications